Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy.

Moretti S, Cafaro A, Tripiciano A, Picconi O, Buttò S, Ensoli F, Sgadari C, Monini P, Ensoli B.

Expert Rev Vaccines. 2020 Jan;19(1):71-84. doi: 10.1080/14760584.2020.1712199. Epub 2020 Jan 19.

PMID:
31957513
2.

The Aryl Hydrocarbon Receptor Is Expressed in Thyroid Carcinoma and Appears to Mediate Epithelial-Mesenchymal-Transition.

Moretti S, Nucci N, Menicali E, Morelli S, Bini V, Colella R, Mandarano M, Sidoni A, Puxeddu E.

Cancers (Basel). 2020 Jan 7;12(1). pii: E145. doi: 10.3390/cancers12010145.

3.

Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease.

Cafaro A, Tripiciano A, Picconi O, Sgadari C, Moretti S, Buttò S, Monini P, Ensoli B.

Vaccines (Basel). 2019 Aug 26;7(3). pii: E99. doi: 10.3390/vaccines7030099. Review.

4.

Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer.

Antognelli C, Moretti S, Frosini R, Puxeddu E, Sidoni A, Talesa VN.

Cells. 2019 Jun 6;8(6). pii: E547. doi: 10.3390/cells8060547.

5.

Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.

Giannini R, Moretti S, Ugolini C, Macerola E, Menicali E, Nucci N, Morelli S, Colella R, Mandarano M, Sidoni A, Panfili M, Basolo F, Puxeddu E.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3557-3575. doi: 10.1210/jc.2018-01167.

PMID:
30882858
6.

Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study.

Sgadari C, Monini P, Tripiciano A, Picconi O, Casabianca A, Orlandi C, Moretti S, Francavilla V, Arancio A, Paniccia G, Campagna M, Bellino S, Meschiari M, Nozza S, Sighinolfi L, Latini A, Muscatello A, Saracino A, Di Pietro M, Galli M, Cafaro A, Magnani M, Ensoli F, Ensoli B.

Front Immunol. 2019 Feb 13;10:233. doi: 10.3389/fimmu.2019.00233. eCollection 2019.

7.

Anti-hTERT siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft.

Lombardo GE, Maggisano V, Celano M, Cosco D, Mignogna C, Baldan F, Lepore SM, Allegri L, Moretti S, Durante C, Damante G, Fresta M, Russo D, Bulotta S, Puxeddu E.

Mol Cancer Ther. 2018 Jun;17(6):1187-1195. doi: 10.1158/1535-7163.MCT-17-0559. Epub 2018 Mar 21.

8.

Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.

Ayroldi E, Petrillo MG, Marchetti MC, Cannarile L, Ronchetti S, Ricci E, Cari L, Avenia N, Moretti S, Puxeddu E, Riccardi C.

Cell Death Dis. 2018 Feb 21;9(3):305. doi: 10.1038/s41419-018-0346-y.

9.

"cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies".

Cafaro A, Sgadari C, Picconi O, Tripiciano A, Moretti S, Francavilla V, Pavone Cossut MR, Buttò S, Cozzone G, Ensoli F, Monini P, Ensoli B.

Expert Rev Vaccines. 2018 Feb;17(2):115-126. doi: 10.1080/14760584.2018.1418666. Epub 2017 Dec 22. Review.

PMID:
29243498
10.

Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1.

Moretti S, Menicali E, Nucci N, Voce P, Colella R, Melillo RM, Liotti F, Morelli S, Fallarino F, Macchiarulo A, Santoro M, Avenia N, Puxeddu E.

J Biol Chem. 2017 Feb 3;292(5):1785-1797. doi: 10.1074/jbc.M116.745448. Epub 2016 Dec 19.

11.

HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.

Ensoli B, Nchabeleng M, Ensoli F, Tripiciano A, Bellino S, Picconi O, Sgadari C, Longo O, Tavoschi L, Joffe D, Cafaro A, Francavilla V, Moretti S, Pavone Cossut MR, Collacchi B, Arancio A, Paniccia G, Casabianca A, Magnani M, Buttò S, Levendal E, Ndimande JV, Asia B, Pillay Y, Garaci E, Monini P; SMU-MeCRU study group.

Retrovirology. 2016 Jun 9;13(1):34. doi: 10.1186/s12977-016-0261-1.

12.

Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation.

Morelli S, Reboldi G, Moretti S, Menicali E, Avenia N, Puxeddu E.

Endocrine. 2016 Jun;52(3):571-8. doi: 10.1007/s12020-015-0788-2. Epub 2015 Nov 4.

PMID:
26537478
13.

HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.

Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B.

Retrovirology. 2015 Apr 29;12:33. doi: 10.1186/s12977-015-0151-y.

14.

Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines.

Titti F, Maggiorella MT, Ferrantelli F, Sernicola L, Bellino S, Collacchi B, Fanales Belasio E, Moretti S, Pavone Cossut MR, Belli R, Olivieri E, Farcomeni S, Compagnoni D, Michelini Z, Sabbatucci M, Sparnacci K, Tondelli L, Laus M, Cafaro A, Caputo A, Ensoli B.

PLoS One. 2014 Oct 30;9(10):e111360. doi: 10.1371/journal.pone.0111360. eCollection 2014.

15.

Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.

Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C, Alunno A, de Biase D, Bini V, Mameli MG, Filetti S, Gerli R, Macchiarulo A, Melillo RM, Tallini G, Santoro M, Puccetti P, Avenia N, Puxeddu E.

J Clin Endocrinol Metab. 2014 May;99(5):E832-40. doi: 10.1210/jc.2013-3351. Epub 2014 Feb 11.

PMID:
24517146
16.

HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.

Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A, Nappi F, Longo O, Bellino S, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone P, Leone P, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MP, Titti F, Banci L, Dallocchio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, Ensoli B.

PLoS One. 2012;7(11):e48781. doi: 10.1371/journal.pone.0048781. Epub 2012 Nov 13.

17.

Gemcitabine-loaded biocompatible nanocapsules for the effective treatment of human cancer.

Paolino D, Cosco D, Celano M, Moretti S, Puxeddu E, Russo D, Fresta M.

Nanomedicine (Lond). 2013 Feb;8(2):193-201. doi: 10.2217/nnm.12.101. Epub 2012 Oct 24.

PMID:
23094834
18.

Modifications in the papillary thyroid cancer gene profile over the last 15 years.

Romei C, Fugazzola L, Puxeddu E, Frasca F, Viola D, Muzza M, Moretti S, Nicolosi ML, Giani C, Cirello V, Avenia N, Rossi S, Vitti P, Pinchera A, Elisei R.

J Clin Endocrinol Metab. 2012 Sep;97(9):E1758-65. doi: 10.1210/jc.2012-1269. Epub 2012 Jun 28.

PMID:
22745248
19.

Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.

Menicali E, Moretti S, Voce P, Romagnoli S, Avenia N, Puxeddu E.

Front Endocrinol (Lausanne). 2012 May 22;3:67. doi: 10.3389/fendo.2012.00067. eCollection 2012.

20.

Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells.

D'Agostino M, Voce P, Celano M, Sponziello M, Moretti S, Maggisano V, Verrienti A, Durante C, Filetti S, Puxeddu E, Russo D.

Thyroid. 2012 Feb;22(2):138-44. doi: 10.1089/thy.2011.0060. Epub 2011 Dec 22.

PMID:
22191389

Supplemental Content

Loading ...
Support Center